Fig. 6.

TKI reduce the capacity of moDC to induce T-cell responses. MLR of imatinib-, nilotinib-, or dasatinib-treated moDC with allogenic T cells were performed in the presence or absence (“none”) of blocking anti-osteoactivin antibody (black bars) with goat IgG serving as isotype control (gray bars). moDC were incubated with or without a 3 μM imatinib, b 3 μM nilotinib or c 10 nM dasatinib. Untreated moDC were included in each experiment (white bars). d Incubation of untreated moDC with anti-osteoactivin antibody. Means with standard deviations of quadruple results are shown. Stars indicate significance (*P < 0.05, **P < 0.01, ***P < 0.003, n.s. not significant). Representative results from at least three independent experiments using PBMC of different donors are shown